Corey Casper Selected Research

siltuximab

1/2021	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
3/2020	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
10/2015	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
10/2015	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
4/2015	Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
8/2014	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
7/2013	A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
8/2010	Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Corey Casper Research Topics

Disease

23	Neoplasms (Cancer) 01/2022 - 05/2008
21	Infections 01/2021 - 04/2002
9	Castleman Disease (Castleman's Disease) 01/2021 - 03/2004
8	HIV Infections (HIV Infection) 01/2021 - 06/2004
7	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2018 - 10/2002
4	Viremia 01/2018 - 01/2009
4	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2015 - 08/2010
3	Fatigue 03/2020 - 07/2013
3	Multi-centric Castleman's Disease 11/2017 - 08/2014
3	Anemia 03/2017 - 07/2013
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/2015 - 03/2004
2	Epstein-Barr Virus Infections 01/2021 - 05/2014
2	Leprosy (Hansen's Disease) 11/2020 - 10/2018
2	Neutropenia 03/2020 - 07/2013
2	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2019 - 03/2017
2	Malaria 01/2018 - 09/2013
2	Coinfection 01/2018 - 09/2014
2	Death (Near-Death Experience) 01/2018 - 12/2017
2	Thrombocytopenia (Thrombopenia) 03/2017 - 07/2013
2	Hepatitis B 01/2017 - 01/2016
2	Sepsis (Septicemia) 01/2017 - 08/2014
2	Hematologic Neoplasms (Hematological Malignancy) 05/2016 - 02/2010
2	Hepatitis C 01/2016 - 09/2003
2	Leukopenia 10/2015 - 07/2013
2	Hypercholesterolemia 10/2015 - 07/2013
2	Hypertriglyceridemia 10/2015 - 07/2013
2	Acquired Immunodeficiency Syndrome (AIDS) 02/2012 - 03/2011
1	Severe Acute Respiratory Syndrome 06/2022
1	Uterine Cervical Dysplasia 01/2022
1	Urinary Retention 03/2020
1	Vomiting 03/2020
1	Nausea 03/2020
1	Disease Progression 03/2020
1	Hypertension (High Blood Pressure) 03/2020
1	Major Depressive Disorder (Major Depressive Disorders) 11/2017
1	Anhedonia 11/2017
1	Rheumatoid Arthritis 11/2017
1	Cytopenia 03/2017
1	Proteinuria 03/2017
1	Hypoalbuminemia 03/2017
1	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2017
1	Cytokine Release Syndrome 03/2017
1	Edema (Dropsy) 03/2017
1	Thrombocytosis (Thrombocythemia) 03/2017
1	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 03/2017
1	Latent Infection 01/2017
1	Septic Shock (Toxic Shock Syndrome) 01/2017
1	Congenital Abnormalities (Deformity) 01/2017
1	Mycoses (Diseases, Fungus) 01/2016
1	Lymphopenia (Lymphocytopenia) 10/2015
1	Polycythemia (Erythrocytosis) 10/2015

Drug/Important Bio-Agent (IBA)

11	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2004
9	Interleukin-6 (Interleukin 6)IBA 01/2018 - 04/2005
8	siltuximabIBA 01/2021 - 08/2010
6	VaccinesIBA 06/2022 - 06/2013
6	Monoclonal AntibodiesIBA 11/2017 - 08/2010
5	RNA (Ribonucleic Acid)IBA 06/2022 - 03/2011
5	Antiviral Agents (Antivirals)IBA 01/2021 - 11/2009
5	Pharmaceutical PreparationsIBA 01/2016 - 09/2003
4	AntibodiesIBA 01/2021 - 10/2002
3	AntigensIBA 11/2020 - 03/2017
3	Protease Inhibitors (Protease Inhibitor)IBA 09/2013 - 06/2011
3	Nelfinavir (Viracept)FDA Link 09/2013 - 06/2011
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2018
2	Glycoproteins (Glycoprotein)IBA 01/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 10/2015
2	Neutralizing AntibodiesIBA 11/2017 - 06/2004
2	InterleukinsIBA 10/2015 - 08/2014
2	insulin receptor-related receptor (IRR)IBA 08/2015 - 01/2009
2	HIV Protease InhibitorsIBA 09/2013 - 08/2011
2	Ganciclovir (Cytovene)FDA LinkGeneric 08/2011 - 03/2004
1	mRNA VaccinesIBA 06/2022
1	Lipid NanoparticlesIBA 06/2022
1	Acetic Acid (Vinegar)FDA LinkGeneric 01/2022
1	Cytidine DeaminaseIBA 01/2019
1	Immunoglobulin Variable RegionIBA 01/2019
1	Immunoglobulin G (IgG)IBA 01/2019
1	LipopolysaccharidesIBA 10/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2018
1	Peptides (Polypeptides)IBA 01/2018
1	N-acetoacetyl-N-deacetylcolchicineIBA 01/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	CytokinesIBA 11/2017
1	NucleotidesIBA 03/2017
1	IgKIBA 03/2017
1	Immunoglobulins (Immunoglobulin)IBA 03/2017
1	C-Reactive ProteinIBA 03/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2017
1	Tenofovir (Viread)FDA Link 01/2017
1	GlucocorticoidsIBA 05/2016
1	CholesterolIBA 10/2015

Therapy/Procedure

13	Therapeutics 01/2022 - 04/2002
8	Drug Therapy (Chemotherapy) 01/2019 - 03/2004
7	Highly Active Antiretroviral Therapy (HAART) 09/2014 - 05/2008
3	Art Therapy 01/2017 - 02/2012
2	Palliative Care (Palliative Therapy) 01/2018 - 04/2013
2	Cell Transplantation 05/2016 - 02/2010
1	Radiotherapy 02/2020
1	Continuity of Patient Care 01/2019
1	Immunotherapy 10/2018